查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1523038

HER2 测试市场报告：2030 年趋势、预测与竞争分析

HER2 Testing Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

HER2 检测趋势与预测

预计 2024 年至 2030 年，全球 HER2 检测市场将以 7.1% 的复合年增长率成长。该市场的主要驱动力是个人化医疗方法的日益重要以及乳癌和胃癌盛行率的迅速增加。全球 HER2 检测市场的未来前景广阔，医院和诊断实验室市场充满机会。

分段 HER2 测试

该研究包括按技术、癌症类型、最终用途和地区对全球 HER2 检测的预测。

HER2 测试市场洞察

Lucintel 预测，由于其成本效益和快速週转时间，萤光原位杂合反应(FISH) 在预测期内仍将是最大的细分市场。

由于专业医疗设备和基础设施的可用性，医院可能仍然是该市场中最大的部分。

北美乳癌盛行率很高，在预测期内可能仍然是最大的地区。

常问问题

Q1.市场成长预测是多少：

A1. 全球 HER2 检测市场预估 2024 年至 2030 年复合年增长率为 7.1%。

Q2. 影响市场成长的关键驱动因素是：

A2. 该市场的主要驱动力是个人化医疗方法的日益重要以及乳癌和胃癌盛行率的迅速增加。

Q3.市场的主要细分市场是：

A3.HER2 检测市场的未来看起来充满希望，医院和诊断实验室市场也充满机会。

Q4.市场的主要企业是：

A4. HER2检测主要企业如下：

  • Abbott
  • Hoffmann-La Roche
  • Agilent Technologies
  • Thermo Fisher Scientific
  • Leica Biosystems
  • Empire Genomics
  • Bio-Genex Laboratories

Q5.未来最大的细分市场是什么？

A5.Lucintel 预计萤光原位杂合反应(FISH) 由于其成本效益和快速週转时间，在预测期内仍将是最大的细分市场。

Q6.未来五年预计哪些地区的市场成长最大？

A6. 由于乳癌盛行率较高，北美在预测期内仍是最大的地区。

Q7. 可以客製化报告吗？

A7。

目录

第一章执行摘要

第二章 全球 HER2 检测市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球 HER2 检测市场趋势（2018-2023）与预测（2024-2030）
  • HER2 技术检测的全球市场
    • 萤光原位杂合反应（FISH）
    • 双探头
    • 单探头
    • 显色杂合反应(CISH)
    • 银敏原位杂合反应
  • 以癌症类型分類的 HER2 检测的全球市场
    • 乳癌
    • 胃癌
  • 按最终用途分類的 HER2 测试全球市场
    • 医院
    • 诊断实验室
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 按地区分類的 HER2 检测市场
  • 北美HER2检测市场
  • 欧洲HER2检测市场
  • 亚太 HER2 测试市场
  • 其他地区HER2检测市场

第五章 竞争分析

  • 产品系列分析
  • 业务整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • HER2 检测市场的技术成长机会
    • 按癌症类型分類的全球 HER2 检测市场成长机会
    • 按最终用途分類的全球 HER2 测试市场成长机会
    • 全球 HER2 测试市场成长机会（按地区）
  • 全球HER2检测市场新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球 HER2 检测市场的产能
    • 全球 HER2 检测市场的合併、收购与合资
    • 认证和许可

第七章主要企业概况

  • Abbott
  • Hoffmann-La Roche
  • Agilent Technologies
  • Thermo Fisher Scientific
  • Leica Biosystems
  • Empire Genomics
  • Bio-Genex Laboratories
简介目录

HER2 Testing Trends and Forecast

The future of the global HER2 testing market looks promising with opportunities in the hospitals and diagnostic laboratories markets. The global HER2 testing market is expected to grow with a CAGR of 7.1% from 2024 to 2030. The major drivers for this market are increasing significance of personalized medical approaches and surge in the prevalence of breast and gastric cancers.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

HER2 Testing by Segment

The study includes a forecast for the global HER2 testing by technique, cancer type, end use, and region.

HER2 Testing Market by Technique [Shipment Analysis by Value from 2018 to 2030]:

  • Fluorescence In Situ Hybridization
  • Dual-Probe
  • Single-Probe
  • Chromogenic In Situ Hybridization
  • Silver-Enhanced In Situ Hybridization

HER2 Testing Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

  • Breast Cancer
  • Gastric Cancer

HER2 Testing Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Diagnostic Laboratories
  • Others

HER2 Testing Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of HER2 Testing Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies HER2 testing companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the HER2 testing companies profiled in this report include-

  • Abbott
  • Hoffmann-La Roche
  • Agilent Technologies
  • Thermo Fisher Scientific
  • Leica Biosystems
  • Empire Genomics
  • Bio-Genex Laboratories

HER2 Testing Market Insights

Lucintel forecasts that fluorescence in situ hybridization will remain the largest segment over the forecast period due to their cost-effectiveness and faster turnaround times.

Within this market, hospitals will remain the largest segment due to availability of specialized medical equipment and infrastructure.

North America will remain the largest region over the forecast period due to high prevalence of breast cancer.

Features of the Global HER2 Testing Market

Market Size Estimates: HER2 testing market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: HER2 testing market size by technique, cancer type, end use, and region in terms of value ($B).

Regional Analysis: HER2 testing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different techniques, cancer types, end uses, and regions for the HER2 testing market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the HER2 testing market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for HER2 testing market?

Answer: The global HER2 testing market is expected to grow with a CAGR of 7.1% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the HER2 testing market?

Answer: The major drivers for this market are increasing significance of personalized medical approaches and surge in the prevalence of breast and gastric cancers.

Q3. What are the major segments for HER2 testing market?

Answer: The future of the HER2 testing market looks promising with opportunities in the hospitals and diagnostic laboratories markets.

Q4. Who are the key HER2 testing market companies?

Answer: Some of the key HER2 testing companies are as follows:

  • Abbott
  • Hoffmann-La Roche
  • Agilent Technologies
  • Thermo Fisher Scientific
  • Leica Biosystems
  • Empire Genomics
  • Bio-Genex Laboratories

Q5. Which HER2 testing market segment will be the largest in future?

Answer: Lucintel forecasts that fluorescence in situ hybridization will remain the largest segment over the forecast period due to their cost-effectiveness and faster turnaround times.

Q6. In HER2 testing market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to high prevalence of breast cancer.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the HER2 testing market by technique (fluorescence in situ hybridization, dual-probe, single-probe, chromogenic in situ hybridization, and silver-enhanced in situ hybridization), cancer type (breast cancer and gastric cancer), end use (hospitals, diagnostic laboratories, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global HER2 Testing Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global HER2 Testing Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global HER2 Testing Market by Technique
    • 3.3.1: Fluorescence in situ hybridization
    • 3.3.2: Dual-probe
    • 3.3.3: Single-probe
    • 3.3.4: Chromogenic in situ hybridization
    • 3.3.5: Silver-enhanced in situ hybridization
  • 3.4: Global HER2 Testing Market by Cancer Type
    • 3.4.1: Breast Cancer
    • 3.4.2: Gastric Cancer
  • 3.5: Global HER2 Testing Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Diagnostic Laboratories
    • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global HER2 Testing Market by Region
  • 4.2: North American HER2 Testing Market
    • 4.2.1: North American HER2 Testing Market by Technique: Fluorescence in situ hybridization, Dual-probe, Single-probe, Chromogenic in situ hybridization, and Silver-enhanced in situ hybridization
    • 4.2.2: North American HER2 Testing Market by End Use: Hospitals, Diagnostic Laboratories, and Others
  • 4.3: European HER2 Testing Market
    • 4.3.1: European HER2 Testing Market by Technique: Fluorescence in situ hybridization, Dual-probe, Single-probe, Chromogenic in situ hybridization, and Silver-enhanced in situ hybridization
    • 4.3.2: European HER2 Testing Market by End Use: Hospitals, Diagnostic Laboratories, and Others
  • 4.4: APAC HER2 Testing Market
    • 4.4.1: APAC HER2 Testing Market by Technique: Fluorescence in situ hybridization, Dual-probe, Single-probe, Chromogenic in situ hybridization, and Silver-enhanced in situ hybridization
    • 4.4.2: APAC HER2 Testing Market by End Use: Hospitals, Diagnostic Laboratories, and Others
  • 4.5: ROW HER2 Testing Market
    • 4.5.1: ROW HER2 Testing Market by Technique: Fluorescence in situ hybridization, Dual-probe, Single-probe, Chromogenic in situ hybridization, and Silver-enhanced in situ hybridization
    • 4.5.2: ROW HER2 Testing Market by End Use: Hospitals, Diagnostic Laboratories, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global HER2 Testing Market by Technique
    • 6.1.2: Growth Opportunities for the Global HER2 Testing Market by Cancer Type
    • 6.1.3: Growth Opportunities for the Global HER2 Testing Market by End Use
    • 6.1.4: Growth Opportunities for the Global HER2 Testing Market by Region
  • 6.2: Emerging Trends in the Global HER2 Testing Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global HER2 Testing Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global HER2 Testing Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Abbott
  • 7.2: Hoffmann-La Roche
  • 7.3: Agilent Technologies
  • 7.4: Thermo Fisher Scientific
  • 7.5: Leica Biosystems
  • 7.6: Empire Genomics
  • 7.7: Bio-Genex Laboratories